Wilmington, DE –Dec 02, 2021 — An American tech start-up has patented the first biotechnology solution enabling users to instantly detect pre-symptomatic or asymptomatic Covid-19 infections through unique odors emitted by the human body.
Global e·dentity’s™ newest patent US 10,880,303 is the first U.S. patent issued to detect the Covid family of viruses by its biometric identity from markers using chemosensory scanning (smell) that identifies the unique chemical odor signature associated with the metabolism of Covid-19 infection, thus quickly identifying individuals who are asymptomatic or pre-symptomatic.